Moberg Pharma ABFRA:MB8 +2.28%59 Quick Ratio is 12.80 as of Mar. 2026, which is 168% above its 10-year median of 4.77. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.09. The stock has 1 warning sign investors should review. Among 997 Drug Manufacturers companies, Moberg Pharma AB ranks better than 95.69% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Moberg Pharma AB's quick ratio for the quarter that ended in Mar. 2026 was 12.80.
Moberg Pharma AB has a quick ratio of 12.80. It generally indicates good short-term financial strength.
The historical rank and industry rank for Moberg Pharma AB's Quick Ratio or its related term are showing as below:
FRA:MB8'
s Quick Ratio Range Over the Past 10 Years
Min: 1.28 Med: 4.77 Max: 22.03
Current: 12.8
During the past 13 years, Moberg Pharma AB's highest Quick Ratio was 22.03. The lowest was 1.28. And the median was 4.77.
FRA:MB8's Quick Ratio is ranked better than 95.69% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs FRA:MB8: 12.80
Moberg Pharma AB (FRA:MB8) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Moberg Pharma AB Quick Ratio Related Terms
Moberg Pharma AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Moberg Pharma AB's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moberg Pharma AB (FRA:MB8) has a Quick Ratio of 12.80 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Moberg Pharma AB and its competitors. This is 168% above median its historical median of 4.77. Over the past decade, Moberg Pharma AB's Quick Ratio has ranged from 1.28 to 22.03. According to the industry distribution chart, Moberg Pharma AB ranks #43 out of 997 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Moberg Pharma AB's Quick Ratio too high?
Moberg Pharma AB's current Quick Ratio of 12.80 is 168% above median its 10-year median of 4.77. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 22.03. The Drug Manufacturers industry median Quick Ratio is 1.45. Moberg Pharma AB's value of 12.80 is 782.8% above this industry median. Based on the distribution chart, Moberg Pharma AB ranks #43 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #43 out of 997 companies for Quick Ratio. This places Moberg Pharma AB in the top 4% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Moberg Pharma AB's value of 12.80 is 782.8% above this benchmark. Historically, Moberg Pharma AB's own Quick Ratio has ranged from 1.28 to 22.03 over the past decade. While the company's 10-year median is 4.77 vs. the industry median of 1.45, Moberg Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moberg Pharma AB's current Quick Ratio of 12.80 is 782.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Moberg Pharma AB and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current Quick Ratio is 12.80, which is 168% above median its own 10-year median of 4.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Quick Ratio of 12.80. The stock's GF Value™ is €1.09, compared to a current price of €0.81 — trading 26% below its estimated fair value. The current Quick Ratio is 12.80, which is 168% above median its 10-year median of 4.77 and 782.8% above the Drug Manufacturers industry median of 1.45. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Quick Ratio is 12.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of €0.81 is trading 26% below its estimated GF Value™ of €1.09.
Key valuation signals for FRA:MB8:
Quick Ratio: 12.80 (168% above median its 10-year median of 4.77)
GF Value™: €1.09 vs. price of €0.81 (26% below fair value)
Industry Position: 782.8% above the Drug Manufacturers median (#43 of 997)
No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score
Get the complete analysis for FRA:MB8
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MB8 has been successfully added to your 
